Ono Pharmaceutical Co Ltd
TSE:4528
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 606
2 681
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ono Pharmaceutical Co Ltd
Ono Pharmaceutical Co Ltd
Other Equity
Ono Pharmaceutical Co Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ono Pharmaceutical Co Ltd
TSE:4528
|
Other Equity
¥17.8B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Other Equity
¥2.1T
|
CAGR 3-Years
66%
|
CAGR 5-Years
75%
|
CAGR 10-Years
17%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Other Equity
¥245.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
5%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Other Equity
¥237.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Other Equity
¥2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Other Equity
¥463.3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
37%
|
CAGR 10-Years
11%
|
|
Ono Pharmaceutical Co Ltd
Glance View
In the bustling city of Osaka, Japan, Ono Pharmaceutical Co., Ltd. stands as a venerable institution with roots tracing back over three centuries. Origination in 1717 as an apothecary, Ono has evolved into a leading biopharmaceutical company renowned for its pioneering work in immunology. They have a rich history of innovation in drug development, marked by the success of their groundbreaking anti-cancer agent, Opdivo. This is a product of their intensive research and development in the field of immune checkpoint inhibitors, a class of drugs that revolutionizes cancer treatment by bolstering the body's natural defenses to combat malignant cells. Ono’s commitment to R&D, underscored by substantial investment, remains its cornerstone, transforming complex scientific concepts into therapeutic products. The essence of Ono Pharmaceutical’s business model rests on its adeptness at translating scientific excellence into commercial success. They operate within two primary segments: pharmaceutical products and clinical testing-related services. The pharmaceutical segment, the larger of the two, is the engine driving revenue through the development and global distribution of prescription drugs, focusing extensively on treatments in the central nervous system, cancer, and infectious diseases. Ono leverages strategic alliances with global pharmaceutical giants, facilitating broader distribution networks and shared research endeavors, thus amplifying their market presence and financial returns. Their strategy encapsulates a cycle of discovery, development, and commercialization, continually striving to deliver innovative medicinal solutions that enhance the quality of life worldwide.
See Also
What is Ono Pharmaceutical Co Ltd's Other Equity?
Other Equity
17.8B
JPY
Based on the financial report for Sep 30, 2024, Ono Pharmaceutical Co Ltd's Other Equity amounts to 17.8B JPY.
What is Ono Pharmaceutical Co Ltd's Other Equity growth rate?
Other Equity CAGR 10Y
-4%
Over the last year, the Other Equity growth was -69%. The average annual Other Equity growth rates for Ono Pharmaceutical Co Ltd have been -36% over the past three years , -22% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
